PMID: 11905735Mar 22, 2002Paper

Minimal residual disease in leukaemia patients

The Lancet Oncology
T SzczepanskiJ J van Dongen

Abstract

Because of developments in diagnosis of haemopoietic malignant diseases during the past two decades, routine and reliable identification of very low numbers of malignant cells, known as minimal residual disease (MRD), is now possible. Several large-scale studies have shown that monitoring of MRD in haemopoietic malignant disease predicts clinical outcome. In acute lymphoblastic leukaemia, MRD detection is useful for evaluating early response to treatment and consequently for improving stratification, including treatment reduction. In acute promyelocytic leukaemia and chronic myeloid leukaemia, MRD information at specific time points enables effective early treatment intervention. MRD monitoring is also possible in other leukaemia subtypes, but in these disorders the clinical value of MRD detection is not yet known.

References

Feb 19, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·J L SchultzeJ G Gribben
Aug 5, 2000·Cytometry·R van den BeemdJ J van Dongen
May 1, 2007·Current Hematologic Malignancy Reports·Anna van RhenenGerrit Jan Schuurhuis
Jul 1, 1993·Trends in Ecology & Evolution·T Klinger

❮ Previous
Next ❯

Citations

Jan 30, 2009·JAMA : the Journal of the American Medical Association·Jun J YangMary V Relling
Feb 3, 2007·Journal of Applied Genetics·Justyna JółkowskaMałgorzata Dawidowska
Jul 1, 2008·Current Hematologic Malignancy Reports·Dario Campana
May 15, 2010·Current Hematologic Malignancy Reports·Dario Campana
Mar 14, 2003·Cancer Treatment Reviews·Jeffrey E Rubnitz, Ching-Hon Pui
Nov 1, 2003·Best Practice & Research. Clinical Haematology·María B VidrialesDario Campana
Nov 1, 2003·Best Practice & Research. Clinical Haematology·Tomasz SzczepańskiJacques J M van Dongen
May 4, 2012·Leukemia·J J M van DongenUNKNOWN EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
Apr 16, 2002·Current Problems in Pediatric and Adolescent Health Care·Ka Wah Chan
Sep 29, 2005·Hematology·J J M van DongenA W Langerak
Nov 20, 2008·Radiation Protection Dosimetry·Martin Schrappe
Dec 20, 2002·Current Opinion in Oncology·Yaddanapudi Ravindranath
Feb 7, 2003·Journal of Pediatric Hematology/oncology·Geoffrey A M NealeChing-Hon Pui
Jun 5, 2004·Acta Haematologica·Dario Campana, Elaine Coustan-Smith
Feb 5, 2011·The Journal of Clinical Investigation·Axel WeberHolger Christiansen
Jun 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elaine Coustan-SmithDario Campana
Jun 17, 2006·Clinical Chemistry and Laboratory Medicine : CCLM·Tomasz SzczepańskiJacques J M van Dongen
Sep 24, 2004·The Tohoku Journal of Experimental Medicine·Yasuo TohmiyaTakeshi Sasaki
Mar 25, 2005·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Zvonko MagićDragana Stamatović
Dec 29, 2013·European Journal of Clinical Pharmacology·Sunitha KodidelaBiswajit Dubashi
Apr 18, 2014·Nature Reviews. Cancer·Kirill S KorolevJeff Gore
Aug 5, 2003·Current Oncology Reports·María-Belén VidrialesJesús F San-Miguel
Feb 24, 2016·Current Hematologic Malignancy Reports·Taiga NishihoriKenneth H Shain
Jun 24, 2015·Cytometry. Part B, Clinical Cytometry·Juan Flores-MonteroAlberto Orfao
Mar 3, 2004·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Alberto OrfaoJesus San Miguel
May 4, 2010·The Lancet Oncology·Tomasz SzczepańskiJacques J M van Dongen
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Sep 26, 2009·Clinical Lymphoma & Myeloma·David ShookDario Campana
Dec 23, 2008·Seminars in Hematology·Dario Campana
Apr 24, 2007·Best Practice & Research. Clinical Haematology·F Dazzi, C Fozza
Aug 26, 2006·Immunology and Allergy Clinics of North America·Luis EscribanoUNKNOWN Red Española de Mastocitosis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.